⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Medicilon and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Medicilon
↗Shanghai, China
Medicilon is a leading integrated Contract Research Organization (CRO) providing comprehensive preclinical R&D services to pharmaceutical and biotechnology companies worldwide. Founded in 2004, the company offers a one-stop platform spanning drug discovery, pharmaceutical research, and preclinical studies, including GLP-compliant pharmacology, DMPK, and toxicology.
The company supports the global biomedical industry by accelerating the path from initial discovery to IND application. With over 2,000 scientists and staff, Medicilon has assisted in more than 2,000 client R&D programs, contributing to over 600 IND filings across various regulatory bodies including the FDA, NMPA, and EMA.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Founded:2004
Ownership:public
Status:operating
STOCK
Exchange:SSE STAR Market
Ticker:688202.SH
PIPELINE
Stage:Discovery
Lead Drug Stage:Preclinical
Modalities:Small molecule, ADC, Cell therapy, Nucleic acid drugs
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Medicilon USA Corp.
Key Partnerships:Global biopharmaceutical companies and research institutions (2000+ active clients)
COMPETITION
Position:Leader
Competitors:WuXi AppTec, Charles River Laboratories, Pharmaron, Crown Bioscience, Frontage Laboratories
LEADERSHIP
Key Executives:
Chunlin Chen - Founder/CEO
LINKS
Website:medicilon.com.cn
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Medicilon. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.